Randomized trial · people
Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1
Checked against the paper Randomized trialPublished by PepVault
The takeaway
Weight lost on tirzepatide in this trial was mostly fat, but about a quarter was lean mass, the same split seen with placebo.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 160
- Published
- 2025
- Journal
- Diabetes Obes Metab
What they tested
The team wanted to know how tirzepatide changes body makeup, meaning fat mass versus lean mass, in adults with obesity or overweight.
How the study was done
A substudy of the randomized, placebo-controlled SURMOUNT-1 trial, using 160 of its 2539 adults with obesity or overweight (124 on tirzepatide, all doses pooled, and 36 on placebo, a dummy treatment). Each person had a DXA scan (dual-energy X-ray absorptiometry, a body scan that measures fat and lean mass) at the start and at week 72.

Model. Individual results vary.
What they found
At week 72, body weight fell by 21.3% with tirzepatide and 5.3% with placebo. Fat mass fell by 33.9% versus 8.2%, and lean mass fell by 10.9% versus 2.6% (p < 0.001 for all three comparisons). In both groups, about 75% of the weight lost was fat mass and about 25% was lean mass. That split held in most subgroups by sex, age and amount of weight lost.
What it doesn’t show
This was a small substudy of one trial, with only 36 people on placebo, and the subgroup results were a post hoc analysis, meaning they were not planned in advance. Doses were pooled, so it does not show differences between doses, and 73% of the group were women.
The paper
Look et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025.
The compound
More studies on Tirzepatide
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZERandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeksRandomized trial · people · 2025
- Tirzepatide: up to 17.5% weight loss at 52 weeks in SURMOUNT-CNRandomized trial · people · 2024
- Every study on Tirzepatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.